🇺🇸 FDA
Patent

US 11724987

Compositions and methods of treating retinal disease

granted A61KA61K31/41A61K31/423

Quick answer

US patent 11724987 (Compositions and methods of treating retinal disease) held by Aldeyra Therapeutics, Inc. expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aldeyra Therapeutics, Inc.
Grant date
Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/41, A61K31/423, A61K31/426, A61K31/435